Inflammation Portfolio

About Gilead

Gilead Sciences is a large, commercial-stage biopharma leader with a 35+ year history of delivering life-changing therapies, most notably in HIV and viral hepatitis. The company has successfully pivoted and expanded its portfolio into oncology and inflammation, supported by a deep pipeline of 53 clinical programs and significant R&D investment of $5.9B in 2024. With over 11,000 employees and a global commercial footprint, Gilead leverages its scientific expertise and financial strength to pursue bold ambitions in areas of high unmet medical need while emphasizing health equity and community partnerships.

Therapeutic Areas